Auxilium Pharmaceuticals’ XIAFLEX drives revenues following launch in US

In a trading update, Auxilium Pharmaceuticals (NASDAQ:AUXL) told investors that its newly launched treatment of Dupuytren’s contracture, XIAFLEX, has generated revenues of $3.1m in the second quarter. The company also highlighted it continues to sign-up new physicians and sites, since it launched the product earlier this year.

“Having completed the first full quarter of the launch of XIAFLEX, the first approved, non-surgical treatment for the treatment of Dupuytren’s contracture, we believe that we are making good progress on our launch objectives as we work to change the treatment paradigm for this disease”,

Related posts:

1. Access Pharmaceuticals hosts OM Symposium in Vancouver ahead of MuGard launch
2. Access Pharma CEO Davis to meet investors in New York ahead of MuGard launch
3. Optimer Pharmaceuticals gets milestone payment from Cempra for macrolide antibiotic
4. TyraTech poised for growth as 2009 revenues climb and product sales triple
5. Gaz Metro books full-year earnings of $158.5M, up from $154.4M; revenues higher